Blood advances最新文献

{"title":"Recurrent Thrombosis and Major Bleeding in Children Treated for VTE.","authors":"Stephanie F Lenahan, Anne Blackmore, Matthew Fenchel, Evan Thomas, Joseph S Palumbo, Cristina Tarango","doi":"10.1182/bloodadvances.2025016135","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025016135","url":null,"abstract":"<p><p>Risk factors for recurrent venous thromboembolism (VTE) in children are poorly understood, and concerns about risks of anticoagulant therapy in children remain. This single-center, cohort with nested case-control study aimed to determine the incidence rate of recurrent thrombosis and associated risk factors and the incidence of major bleeding in children with VTE on therapeutic anticoagulation. We identified 632 patients managed for VTE between January 1, 2015 and December 31, 2022. There was a VTE recurrence rate of 13.7 per 100 person-years. Univariate analysis showed the presence of a central venous catheter (P=0.02), inflammatory bowel disease (P=0.02), and intestinal failure (P=0.03) were significant risk factors for recurrent VTE. In multivariate logistic regression, significant risk factors for recurrence were anatomic venous abnormality (OR 2.8 with 95% CI 1.37, 5.59), the presence of a central venous catheter (OR 2.0 with 95% CI of 1.21, 3.26), and inflammatory bowel disease (OR 3 with 95% CI 1.18, 7.98). Major bleeding on anticoagulation occurred at a rate of 2.2 per 100 person-years. These data demonstrate that this heterogeneous cohort of children had a high risk of VTE recurrence. The overall major bleeding risk with anticoagulation was low. While each patient with VTE needs to be considered individually, these data support the view that perceived bleeding risk should generally not be a major barrier to anticoagulation in the pediatric setting. Moreover, secondary or extended anticoagulation may be considered in children at high risk for recurrence.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.","authors":"Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, Christian R Schultze-Florey, Atef Abdelhafez, Giuliano Filippini Velazquez, Anna Ossami Saidy, Vadim Lesan, Ulf Schnetzke, Andrea Kerkhoff, Ulrike Bacher, Susanne Ghandili, Enver Aydilek, Niklas Gebauer, Thomas Weber, Gerald Georg Wulf, Bertram Glass, Lorenz Thurner, Florian H Heidel, Christoph Schmid, Andreas Viardot, Mathias Hänel, Sascha Dietrich, Thomas Pabst, Francis Ayuketang Ayuk, Bastian von Tresckow, Bjoern Chapuy, Christiane Pott, Fabian Müller, Georg Lenz","doi":"10.1182/bloodadvances.2024015719","DOIUrl":"https://doi.org/10.1182/bloodadvances.2024015719","url":null,"abstract":"<p><p>Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed CAR T-cell therapy (CAR-T) have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in approximately 35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well as common poor prognosis predictors to CAR-T and BsAb therapy, we conducted a multicenter retrospective analysis including 92 relapsed/refractory (r/r) LBCL patients treated with BsAb after CAR-T failure. Overall response rate (ORR) was 43% with a progression-free survival (PFS) of 2.8 months (mo). BsAb patients in early relapse (≤3 mo) achieved a significantly worse outcome (ORR of 29%, PFS 2.2 mo) compared to patients with an intermediate (4-6 mo, ORR 54%, PFS 3.7 mo) or a late relapse (>6 mo, ORR 60%, PFS 10.5 mo). The benefit of later relapse was particularly notable in patients receiving BsAb as first salvage therapy compared to those receiving BsAb in subsequent lines (PFS not reached vs. 2.7 mo; overall survival not reached vs. 9.1 mo). In addition to early relapse/refractory state prior to BsAb, elevated LDH and higher IPI were significant predictors of poor outcomes to BsAb in multivariate Cox-regression analyses. That patients with early relapse following CAR-T respond particularly poorly to BsAb highlights the necessity for alternative treatment options in this high-risk patient cohort.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort.","authors":"Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, Federica Mazzetto, Francesco Angotzi, Anna Maria Frustaci, Monia Marchetti, Riccardo Moia, Alessandro Sanna, Costantino Riemma, Francesca Cibien, Alessandro Noto, Enrico Lista, Myriam Foglietta, Candida Vitale, Vanessa Innao, Martina Bullo, Ester Lovato, Isacco Ferrarini, Costanza Andriola, Laura Ballotta, Idanna Innocenti, Alberto Fresa, Gianmarco Favrin, Marzia Varettoni, Elisa Santambrogio, Lorella Orsucci, Raffaella Pasquale, Massimo Moratti, Luca Laurenti, Marta Coscia, Paolo Sportoletti, Roberto Marasca, Francesca Romana Mauro, Caterina Patti, Enrico Derenzini, Lydia Scarfò, Paolo Ghia, Antonio Cuneo, Alessandra Tedeschi, Livio Trentin, Massimo Gentile, Andrea Visentin","doi":"10.1182/bloodadvances.2025015818","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025015818","url":null,"abstract":"<p><p>Octogenarians represent a significant fraction of patients with Chronic Lymphocytic Leukemia (CLL) but, despite the prevalence of the disease in this age group, limited data is available on the safety and efficacy of novel drugs in this subgroup. We conducted a multicenter, retrospective study enrolling 120 octogenarian patients who received Venetoclax (Ven) regimens in any line. Regarding efficacy, we found Ven to perform similarly to what is reported in younger patients with CLL, with an overall response rate of 91%, a complete response rate of 44% and median progression-free survival of 44 months. Concerning safety, we report a toxicity profile that is consistent with previous reports, with most high-grade adverse events being of hematological or infectious nature, as 37% and 22% of patients experienced neutropenia or infections of grade 3 or higher. As part of our study, we compared the safety and efficacy data we collected with those obtained in a comparable BTKi-treated population. We found that these two treatments were comparable in terms of overall efficacy, barring a higher rate of complete responses with Ven; safety profiles were different among the two groups as BTKi-treated patients had more cardiovascular toxicities (26% vs 4%) and Ven-treated subjects experienced more infectious events (82% vs 49%). Our data points out that Ven-based regimens are safe and effective in octogenarian patients with CLL despite their higher clinical complexity and comorbidity burden and should provide some basis for the design of prospective studies to further evaluate the optimal treatment regimen in this patient population.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states.","authors":"Diego Butera, Aster E Pijning, Nathan G Avery, Carmen Helena Coxon, Clive Metcalfe, Angelina Mimoun, Sebastien Lacroix-Desmazes, Paul Clinton Spiegel, Philip J Hogg","doi":"10.1182/bloodadvances.2025016474","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025016474","url":null,"abstract":"<p><p>Haemophilia A is a chronic life-threatening condition caused by deficiency or dysfunction of plasma coagulation factor VIII (FVIII) and commonly managed by prophylaxis with regular infusion of FVIII protein. A major obstacle to FVIII replacement therapy is the generation of alloantibodies that diminish efficacy. Disulfide bonds link pairs of cysteine residues in proteins and in several proteins have been found to be only partially formed in the mature proteins. FVIII contains 8 disulfide bonds and their redox state in human blood and recombinant FVIII was determined using differential cysteine alkylation and mass spectrometry. All 8 disulfide bonds were found to be unformed in ~10% to ~70% of molecules of FVIII populations, which suggested a conformational flexibility that could favour binding of certain ligands to subsets of FVIII with more or less formed disulfide bonds. To test this hypothesis, the binding of a panel of five patient-derived anti-FVIII antibodies to the population of FVIII disulfide-bonded states was evaluated. All five antibodies bound preferentially to FVIII states where 2 or 3 of the 8 disulfides are significantly more unformed; C1918-C1922 in the A3 domain, C2040-C2188 in the C1 domain and C2193-C2345 in the C2 domain. Disulfide bond mutagenesis experiments and molecular dynamics simulations indicate that this subset of FVIII states have long-range conformational dynamism that favours anti-drug antibody binding. These findings will assist efforts to engineer a FVIII molecule that is less prone to neutralization by anti-drug antibodies and has general implications for autoimmune conditions and antibody drug efficacy.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study.","authors":"Nikhil Yegya-Raman, John P Plastaras, Christopher M Wright, Monica R Chelius, Siqi Zhang, Jonathan A Baron, Harper Hubbeling, Austin J Sim, Timothy J Robinson, Michael D Jain, Brandon S Imber, Beatrice Fregonese, Joachim Yahalom, Colton Ladbury, Savita Dandapani, Chelsea C Pinnix, Jillian R Gunther, Penny Q Fang, Susan Y Wu, Bouthaina S Dabaja, Joanna C Yang, Jessica Chew, Steve Braunstein, Sumi Sinha, Nathan Denlinger, Susan Sun, Stephanie A Terezakis, Gukan Sakthivel, Louis S Constine, Amit K Chowdhry, Patrick M Reagan, Skyler Burke, Yolanda D Tseng, Michael J LaRiviere, Amit Maity, Stephen J Schuster, Elise A Chong, Nicholas B Figura","doi":"10.1182/bloodadvances.2025015855","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025015855","url":null,"abstract":"<p><p>Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refractory B-cell lymphomas (r/r BCL) who received Br-RT followed by CAR-T from 2018-2020 across 10 institutions. Br-RT toxicities were graded per CTCAE v5.0, and cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) per ASTCT Consensus Guidelines. 172 patients (168 large BCL, 3 mantle cell, 1 Burkitt) received Br-RT prior to axicabtagene ciloleucel (73%), tisagenlecleucel (23%), or brexucabtagene autoleucel (2%). At leukapheresis, most patients (74%) had advanced-stage disease and 39% had bulky disease measuring ≥10cm. Comprehensive Br-RT was administered to 39% (n=67) and bridging systemic therapy to 35% (n=60). Among all patients, grade ≥3 Br-RT toxicity occurred in 2% [one grade 5 toxicity], grade ≥3 CRS in 9%, and grade ≥3 ICANS in 24%. Median follow-up was 31.3 months. Two-year PFS and OS were 38% and 53%, respectively. On multivariable analysis, comprehensive Br-RT was associated with superior PFS (HR 0.38, p<0.001) and OS (HR 0.48, p=0.011). Patients with LDH normalization following Br-RT (high pre-Br-RT LDH, normal post-Br-RT LDH) had superior PFS and OS compared to those with high post-Br-RT LDH, and similar PFS and OS compared to those with normal baseline LDH. In this particularly high-risk cohort, Br-RT prior to CAR-T demonstrates an acceptable toxicity profile with favorable clinical outcomes when compared to historical controls. Comprehensive Br-RT and LDH normalization post-Br-RT may be associated with superior PFS and OS.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.","authors":"Miriam Verdu-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro, Aleix Méndez López, Nuria Profitos-Peleja, Fabian Frontzek, Gael Roue, José Luís Mate, Mireia Pellicer, Pau Abrisqueta, Josep Castellví, Mariana Beatriz Bastos Oreiro, Javier Menarguez, Miguel Alcoceba, Eva González Barca, Fina Climent, Antonio Salar, Juan Manuel Sancho, Annette M Staiger, German Ott, Ioannis Anagnostopoulos, Manel Esteller, Georg Lenz, Gustavo Tapia, José-Tomás Navarro","doi":"10.1182/bloodadvances.2025016180","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025016180","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) is an uncommon and aggressive B-cell lymphoma with a poor prognosis. Some studies have described genetic alterations in PBL, but its transcriptome has been scarcely studied and molecular mechanisms driving lymphomagenesis remain poorly understood. Our goal was to delineate transcriptomic profiles to identify potential biomarkers for novel targeted therapy in PBL. RNA sequencing uncovered an enrichment of cell cycle-related genes, including MYC and E2F targets, and genes involved in G2/M checkpoint in PBL. Microarray analyses discovered two microRNA expression signatures depending on the presence of MYC-translocation. Interestingly, miR-150-5p was downregulated, while E2F3 and BIRC5 (survivin), a cell cycle activator and anti-apoptotic regulator respectively, were upregulated. Increasing miR-150-5p in PBL-1 cells induced G1 cell cycle arrest, suppressed proliferation by transcriptionally repressing E2F3, and promoted apoptosis by downregulation of BIRC5. Interestingly, the miR-150-5p tumor suppressor activity was diminished in E2F3-knockdown cells. The combined inhibition of E2F3 and survivin attenuated lymphomagenesis in PBL cells and suppressed tumor growth in a chorioallantoic membrane (CAM)-derived xenograft model of PBL. Overall, our study highlights the pivotal role of the miR-150-5p/E2F3/survivin axis boosting PBL lymphomagenesis and unveils new therapeutic targets for this lymphoma.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma.","authors":"Joshua N Gustine, Andrew R Branagan, Diana D Cirstea, Farah Rexha, Ryan Han, Andrew J Yee, Marcela V Maus, Matthew J Frigault, Noopur S Raje","doi":"10.1182/bloodadvances.2025015981","DOIUrl":"https://doi.org/10.1182/bloodadvances.2025015981","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.","authors":"Mazyar Shadman, Jennifer R Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M O'Brien, Alessandra Tedeschi, Constantine S Tam","doi":"10.1182/bloodadvances.2024014523","DOIUrl":"https://doi.org/10.1182/bloodadvances.2024014523","url":null,"abstract":"<p><p>Bruton tyrosine kinase inhibitors (BTKis) have led to changes in the treatment algorithm for patients with high-risk relapsed/refractory chronic lymphocytic leukemia (R/R CLL), defined based on the presence of genetic mutations. Given the lack of head-to-head trials comparing next-generation BTKis used to treat high-risk R/R disease, a network meta-analysis (NMA) was performed to estimate their relative efficacy. High-risk populations were defined based on the pre-specified definitions within each trial, including patients with del(17p) and/or TP53 mutations in ALPINE (n=150), and ASCEND (n=86), and del(17p)/del(11q) in ELEVATE-RR (n=533). Bayesian NMAs found zanubrutinib to be the most efficacious treatment for high-risk patients, with significantly reduced risk of progression or death compared with ibrutinib (hazard ratio [95% credible interval (CrI)]: 0.49 [0.31, 0.78]), acalabrutinib (0.55 [0.32, 0.94]), and bendamustine + rituximab or idelalisib + rituximab (BR/IR) (0.12 [0.05, 0.26]). Differences in overall survival demonstrated a numerical trend favoring zanubrutinib (probability better ≥80%) compared to ibrutinib (hazard ratio [95% credible interval]: 0.59 [0.31, 1.11]), acalabrutinib (0.72 [0.35, 1.50]) and BR/IR (0.65 [0.23, 1.75]). Rates of response also demonstrated trends favoring zanubrutinib compared to acalabrutinib, with significant results compared to ibrutinib. The NMA suggests that the most efficacious BTKi for patients with high-risk R/R CLL is zanubrutinib.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicenter Cohort Study.","authors":"Emily Sirotich, Saifur R Chowdhury, Dimpy Modi, Gordon H Guyatt, Melanie St John, Kerolos Eisa, Adam Cuker, Carolyn E Beck, Rachael F Grace, Justin W Yan, Shuoyan Ning, Charles T Quinn, Amanda Pfeiffer, Michele P Lambert, Karen Ann Panckeri, Allyson Pishko, Kristine VanAarsen, Ahmed Slim, Kathryn Carrier, Rebecca Geer, Abinaya Arulselvan, Matthew Basara, Brenna Cannon, Ellis J Bloom, Sam J King, Daya Kaur Gill, Laura M Venier, Emily Xu, Ishaq Siddiqui, Bonnie Liu, Timothy Mercier, Taylah Buissereth, Emily M Harris, Enass H Raffa, Joel Livingston, Mahmudur Rahman Chowdhury, Maryam Akbari-Moghaddam, Dongyoung Kim, Lehana Thabane, Dena Zeraatkar, Donald M Arnold","doi":"10.1182/bloodadvances.2024015494","DOIUrl":"https://doi.org/10.1182/bloodadvances.2024015494","url":null,"abstract":"<p><p>Critical bleeding in patients with immune thrombocytopenia (ITP) is a life-threatening hematological emergency. The objective of this study was to describe the frequency, management, and outcomes of critical bleeds among adults and children with ITP. We conducted a retrospective cohort study of patients with ITP who presented to the emergency room (ER) with a platelet count <20 x109/L across 7 centers in the United States and Canada between 2010 and 2019. Of 1226 patients (n=296 adults; n=930 children), 28 (2.3%) had a critical bleed (n=15 adults, median age 68 years; n=13 children, median age 11 years). Of patients with a critical bleed, 12 adults (80.0%) and 6 children (46.2%) had intracranial hemorrhage (ICH). For adults, the common interventions used to treat critical bleeds were platelet transfusions (n=11; 73.3%), corticosteroids (n=10; 66.7%), and intravenous immune globulin (IVIG) (n=8; 53.3%); and for children, common interventions were IVIG (n=10; 76.9%), corticosteroids (n=8; 61.5%), platelet transfusions (n=8; 61.5%), thrombopoietin receptor agonists (n=4; 30.8%), and antifibrinolytic agents (tranexamic acid or aminocaproic acid, n=4; 30.8%). For both adults and children, the most common treatment combination was corticosteroids, IVIG, and platelet transfusion (n=6; 40.0% vs. n=6; 46.2%). The median time from presentation to first treatment was 6.9 hours for adults and 3.5 hours for children. Overall, 9 (32.1%) patients with critical ITP bleeds died, including 7 adults (46.7%) and 2 children (15.4%). Critical bleeding in patients with ITP was rare but frequently fatal, especially among older adults with ICH and when treatments were delayed.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy.","authors":"Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadman, Ailyn C Pérez-Osorio, Keith R Jerome, Wendy M Leisenring, Michael J Boeckh, Joshua A Hill","doi":"10.1182/bloodadvances.2024015164","DOIUrl":"https://doi.org/10.1182/bloodadvances.2024015164","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}